Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...
GlobalData on MSN9h
J&J’s fully subcutaneous Tremfya shows 27.6% clinical remission in UCTremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback